HK Stock Market Move | AKESO (09926) opened nearly 4% higher as Yvoxi's Iterative K drug HARMONi-2 achieved positive results in overall survival.

AKESO (09926) opened nearly 4% higher. As of the time of writing, it rose 3.64%, trading at HK$91.0, with a transaction volume of HK$29.1313 million. On September 3, AKESO announced that its globally pioneering tumor immunotherapy cornerstone drug, Ivosidenib (brand name: Yidafang), outperformed Pembrolizumab in a randomized, double-blind, controlled, multicenter, registrational Phase III clinical study (HARMONi-2/AK112-303) for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with positive PD-L1 expression (PD-L1 TPS 1%). The pre-specified interim analysis of overall survival (OS) assessed by the Independent Data Monitoring Committee (IDMC) showed that the study met the key secondary endpoint for overall survival (OS), achieving statistically significant and clinically beneficial positive results. Pembrolizumab is the most representative drug that launched the era of tumor immunotherapy 1.0, driving significant advances in lung cancer treatment, and has become one of the most commercially successful innovative drugs globally. Based on Pembrolizumab, Ivosidenib further enables patients to achieve substantial benefits, demonstrating its groundbreaking clinical value and immense commercial potential as a next-generation cornerstone tumor immunotherapy drug.